281 related articles for article (PubMed ID: 35008981)
21. Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis.
Makavos G; Ikonomidis I; Andreadou I; Varoudi M; Kapniari I; Loukeri E; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Thymis J; Parissis J; Tsoumani M; Rafouli-Stergiou P; Katsimbri P; Papadavid E
Can J Cardiol; 2020 Jan; 36(1):100-111. PubMed ID: 31606265
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis.
Loft N; Bregnhøj A; Fage S; Nielsen CH; Enevold C; Zachariae C; Iversen L; Skov L
Dermatol Ther; 2021 Nov; 34(6):e15106. PubMed ID: 34418225
[TBL] [Abstract][Full Text] [Related]
23. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
24. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
Blauvelt A
Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
[TBL] [Abstract][Full Text] [Related]
25. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
[TBL] [Abstract][Full Text] [Related]
26. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Psoriasis Area and Severity Index Thresholds as Proxies for Systemic Inflammation on an Individual Patient Level.
Hoffmann JHO; Enk AH
Dermatology; 2022; 238(4):609-614. PubMed ID: 34852349
[TBL] [Abstract][Full Text] [Related]
28. Serum cytokine measurements and biological therapy of psoriasis - Prospects for personalized treatment?
Solberg SM; Sandvik LF; Eidsheim M; Jonsson R; Bryceson YT; Appel S
Scand J Immunol; 2018 Dec; 88(6):e12725. PubMed ID: 30307657
[TBL] [Abstract][Full Text] [Related]
29. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine.
Xu M; Deng J; Xu K; Zhu T; Han L; Yan Y; Yao D; Deng H; Wang D; Sun Y; Chang C; Zhang X; Dai J; Yue L; Zhang Q; Cai X; Zhu Y; Duan H; Liu Y; Li D; Zhu Y; Radstake TRDJ; Balak DMW; Xu D; Guo T; Lu C; Yu X
Theranostics; 2019; 9(9):2475-2488. PubMed ID: 31131048
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.
Kyriakou A; Patsatsi A; Vyzantiadis TA; Sotiriadis D
J Immunol Res; 2014; 2014():467541. PubMed ID: 25759829
[TBL] [Abstract][Full Text] [Related]
31. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
32. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
Morita A; Tani Y; Matsumoto K; Yamaguchi M; Teshima R; Ohtsuki M
J Dermatol; 2020 May; 47(5):452-457. PubMed ID: 32173900
[TBL] [Abstract][Full Text] [Related]
33. Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa.
Navrazhina K; Renert-Yuval Y; Frew JW; Grand D; Gonzalez J; Williams SC; Garcet S; Krueger JG
Br J Dermatol; 2022 Apr; 186(4):684-693. PubMed ID: 34254293
[TBL] [Abstract][Full Text] [Related]
34. The CCL20 and CCR6 axis in psoriasis.
Furue K; Ito T; Tsuji G; Nakahara T; Furue M
Scand J Immunol; 2020 Mar; 91(3):e12846. PubMed ID: 31692008
[TBL] [Abstract][Full Text] [Related]
35. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
36. The psoriasis area and severity index is an independent risk factor for cardiovascular events: A prospective register study.
Svedbom A; Ståhle M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1841-1847. PubMed ID: 37147891
[TBL] [Abstract][Full Text] [Related]
37. A review of secukinumab in psoriasis treatment.
Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
[TBL] [Abstract][Full Text] [Related]
38. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health.
Elnabawi YA; Garshick MS; Tawil M; Barrett TJ; Fisher EA; Lo Sicco K; Neimann AL; Scher JU; Krueger J; Berger JS
J Am Acad Dermatol; 2021 Apr; 84(4):913-920. PubMed ID: 33259876
[TBL] [Abstract][Full Text] [Related]
39. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
